linjc16/ctgov huggingface dataset:
Monitoring Arrhythmia Patients (IMPACT)

Study Overview
=================
Brief Summary
-----------------
Prospective, multicenter, non-randomized study to determine the performance of NUVANT Mobile Cardiac Telemetry system in arrhythmia detection.

Detailed Description
-----------------
Arrhythmia patients will be externally monitored. The collected information will be used to evaluate the NUVANT MCT system.

Official Title
-----------------
Arrhythmia Detection With Adherent Patient Monitoring

Conditions
-----------------
Arrhythmias

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age or older Patients undergoing remote ambulatory electrocardiographic monitoring Exclusion Criteria: Is participating in another clinical study that may confound the results of this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Comparison of Intravascular Injection With Chiba Needle and Whitacre Needle

Study Overview
=================
Brief Summary
-----------------
Caudal epidural injection (CEI) is effective for spinal pain. However, intravascular injection may occur during CEI, which can lead to hematoma, neurologic deficit and local anesthetics systemic toxicity. Whitacre type needle has been reported to be effective for reducing intravascular injection during transforaminal epidural injection. In this study, we compared the Chiba needle and Whitacre needle on incidence of intravascular injection during CEI.

Detailed Description
-----------------
A total of 164 caudal epidural injections were performed in patients with disc herniation or spinal stenosis on lumbosacral region. Patients were randomly allocated to Group Whitacre (n=82) and Group Chiba (n=82). Patients in Group Whitacre received caudal epidural injection using Whitacre type needle and those in Group Chiba received the procedure using Chiba type needle. Intravascular injection was assessed with blood aspiration and angiography during real-time fluoroscopy.

Official Title
-----------------
A Comparison of Intravascular Injection With Chiba Needle and Whitacre Needle During Caudal Epidural Block : a Prospective Study

Conditions
-----------------
Spinal Stenosis Lumbar, Disk Herniated Lumbar

Intervention / Treatment
-----------------
* Device: needle (Chiba)
* Device: needle (Whitacre)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with low back pain and/or leg radicular pain under diagnoses as disc herniation or spinal stenosis Exclusion Criteria: allergy to local anesthetics or contrast medium, coagulopathy, local infection at the injection site, and systemic infection
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group Whitacre<br>Group whitacre receives the whitacre needle during caudal block | Device: needle (Whitacre)<br>* intravascular injection using whitacre needle during caudal epidural block<br>|
| Experimental: Group Chiba<br>Group chiba receives the chiba needle during caudal block | Device: needle (Chiba)<br>* intravascular injection using chiba needle during caudal epidural block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of intravascular injection | incidence of intravascular injection during caudal block | 5 minute |
Gastric Electrical Stimulation for Abdominal Pain in Gastroparesis

Study Overview
=================
Brief Summary
-----------------
To conduct a pilot study to evaluate the effects of new GES programming settings on abdominal pain in patients with gastroparesis and existing GES devices, whose abdominal pain has so far been refractory to drugs and/or devices.

Detailed Description
-----------------
Eligible patients will undergo detailed pain assessments as well as non-invasive physiologic assessment. Patients existing GES devices will be reprogrammed to new setting for 4 week and their GI symptoms including pain will be evaluated by a daily diary. At the end of 4 weeks detailed pain assessments and noninvasive physiologic assessments will be repeated.

Official Title
-----------------
Gastric Electrical Stimulation for Treating Abdominal Pain in Patients With Gastroparesis

Conditions
-----------------
Abdominal Pain

Intervention / Treatment
-----------------
* Device: Enterra


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Should be able to give informed consent for the study Has Enterra GES device in place for at least 2 months Continue to have moderate to severe abdominal pain on at least one pain questionnaire or >5 score (on a scale of 0-10 for pain) on the VAS questionnaire for at least 2 months. Abdominal pain should be either persistent; for example, daily for at least >1 hour, be chronic for >2 months, and refractory to original Enterra GES settings Exclusion Criteria: Unable to provide informed consent Pregnancy Any other active health problems that would render patient unable to complete the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Gastroparesis patients with abdominal pain<br>Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain. | Device: Enterra<br>* To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Abdominal Pain | Abdominal Pain by Brief Pain Inventory. The values are 0-10, with 10 being worse outcome. | 4 weeks |
Study On Discopathie With Modic 1

Study Overview
=================
Brief Summary
-----------------
The chronic lumbago can be associated with an active discopathie, objectified on the MRI by the presence of an inflammatory signal (Modic 1) or greasy (Modic 2) vertebral trays framing the pathological vertebral disk The treatment recommended by t consists in particular of a local infiltration of corticoids which the efficiency is variable according to the patients. The objective of this study is to estimate the efficiency of the local treatment and to highlight some of the factors associated to the advantage of the infiltration by corticoids.

Official Title
-----------------
Study On Discopathie With Modic 1

Conditions
-----------------
Lumbar Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient admitted in Rhumatology service for intra-disc infiltration Chronic pain (>3 monts) VAS >3 MRI stipulating MODIC 1 Exclusion Criteria: radiculalgy radicular VAS< lumbar VAS pregnancy local infection corticoid allergy previous rachial surgery previous spondylodiscite psychiatric disorder MRI contraindication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain VAS ( VISUAL ANALOGIC SCORE) |  | Day 1 - Day 30 |
Acupuncture Feasibility Trial for Dyspnea in Lung Cancer

Study Overview
=================
Brief Summary
-----------------
This is a single arm clinical trial to establish the feasibility of conducting a clinical trial of acupuncture in reducing dyspnea among lung cancer survivors who have completed chemoradiotherapy. Twelve subjects with dyspnea will be recruited to this clinical trial. Up to 10 sessions of acupuncture will be delivered over the course of 8-10 weeks. The primary outcome will be dyspnea as measured by the English version of the Cancer Dyspnea Scale at the completion of the intervention.

Official Title
-----------------
Acupuncture Feasibility Trial for Dyspnea in Lung Cancer

Conditions
-----------------
Lung Cancer, Dyspnea

Intervention / Treatment
-----------------
* Procedure: Acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Lung Cancer (Non small cell and small cell both eligible) Completion of concurrent CRT at least 6 months prior to randomization. Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level) Ability to understand written English -Willingness to adhere to all study-related procedures Age 18 years old ECOG Performance Status 1-3 Exclusion Criteria: Current receipt of therapy for treatment related pneumonitis for 3 weeks. Surgical resection of this LC (lobectomy or pneumonectomy) Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL) Current bleeding disorder by history Life expectancy of 12 weeks, as assessed by primary oncologist

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lung Cancer Patient with Dyspnea<br> | Procedure: Acupuncture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dyspnea |  | 10 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
concurrent chemotherapy, concurrent radiation
Recovery of Walking in Persons With Complete Spinal Cord Injury

Study Overview
=================
Brief Summary
-----------------
We documented the impact of 1 year of underwater treadmill training and supplemental overground walk training in five adults with chronic motor-complete SCI (cSCI) who had not undergone programmed epidural spinal cord stimulation (eSCS).

Detailed Description
-----------------
Regular exposure to self-initiated treadmill walking in water, a unique sensorimotor exercise setting that makes stepping movements easier to perform, may capitalize on the adaptability of the neuromuscular system and enhance locomotor function in persons with cSCI who have not undergone eSCS. In our study, a combined aquatics- and land-based approach to gait training was employed over a 12-month period that featured underwater treadmill training and supplemental overground walk training.

Official Title
-----------------
Recovery of Walking Without Epidural Spinal Cord Stimulation in Adults With Complete Spinal Cord Injury

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Behavioral: Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria At least 21 years of age Presence of traumatic or non-traumatic spinal cord injury for at least 1 year Medical diagnosis of paraplegia (T1 or below) Exclusion Criteria Presence of complex comorbidities that could limit involvement in training activities Surgical implantation or removal of a medical device six months prior to training Skin breakdown Use of electrical implants to promote ambulation

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br>Walk training | Behavioral: Exercise<br>* Underwater treadmill training and supplemental overground walk training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overground walking capacity | Walking Capacity for Spinal Cord Injury (WISCI-II) | Change from Baseline WISCI-II score at 6 months and 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal Cord Injury, Exercise, Walking, Aquatics
Bed Rest, Inactivity and Early Responses

Study Overview
=================
Brief Summary
-----------------
To evaluate the early metabolic responses (whole body and within muscle tissue) to a single day of whole body physical inactivity (i.e. bed-rest), and evaluate the contribution of inactivity per se vs alterations in diet

Official Title
-----------------
Bed Rest, Inactivity and Early Responses

Conditions
-----------------
Metabolic Responses to Inactivity

Intervention / Treatment
-----------------
* Other: Physical inactivity


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy and aged 18-40 y BMI between 18 and 30 Exclusion Criteria: On medication Family history of metabolic disease Diagnosed with any metabolic or cardiovascular conditions BMI < 18 or > 30

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>24 h habitual physical activity fed in energy balance | |
| Experimental: Bed rest matched diet<br>24 hour period of whole body bed-rest with a matched diet | Other: Physical inactivity<br> <br> |
| Experimental: Bed rest balanced diet<br>24 hour period of whole body bed-rest fed in energy balance | Other: Physical inactivity<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose tolerance |  | 24 hours |
Human Vasodilatory Effect of GLP-1

Study Overview
=================
Brief Summary
-----------------
Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries

Official Title
-----------------
Vasodilatory Effect of GLP-1

Conditions
-----------------
Angina, Stable, Coronary Stenosis, Type2 Diabetes

Intervention / Treatment
-----------------
* Drug: GLP-1 (7-36)Amide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Waiting list for elective PCI to LAD Able to give informed consent Over 18 Exclusion Criteria: GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: GLP-1 (7-36)Amide|IV infusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline | Change in coronary microcirculatory resistance from baseline | Change from baseline | 
| Forearm bloodflow ratio with GLP-1 | Peripheral vasodilatory response of GLP-1 | Change from baseline |
The Effect of Femoral Nerve Block on Postoperative Opioid Use After Anterior Cruciate Ligament (ACL) Reconstruction

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effect of a femoral nerve block on opioid requirements following anterior cruciate ligament (ACL) reconstruction. This is a double blind, prospective randomized controlled trial.

Official Title
-----------------
Effect of Femoral Nerve Block on Opioid Requirements Following Anterior Cruciate Ligament Reconstruction: A Double Blind, Prospective Randomized Controlled Trial

Conditions
-----------------
Pain, Postoperative

Intervention / Treatment
-----------------
* Procedure: Administration of a femoral nerve block (bupivacaine HCL)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Schedule for primary elective anterior cruciate ligament reconstruction Tolerance to bupivacaine Tolerance to non-steroidal anti-inflammatory drugs (NSAIDs) Informed consent Exclusion Criteria: Patients who received a femoral nerve block more than 1 hour prior to surgery Complex associated injuries or pre-existing conditions that will delay time to ambulation Children with tibial avulsion fractures Allergic and/or sensitive to bupivacaine and/or NSAIDs 30% over ideal body weight Acute ACL reconstruction (done less than 2 weeks after injury) Pre-existing femoral nerve injury Psychiatric patients on psychotropic agents History of drug or alcohol dependence or recreational drug use Refusal to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative morphine requirement |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain rating |  | immediately post-op | 
| Opioid surgical time |  | time from end of anaesthesia to first requirement of morphine | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ACL reconstruction, morphine sparing, preemptive analgesia, Post-operative pain and post- operative opioid use
Incidence and Effects of Sleep Apnea on Intracerebral Aneurysms

Study Overview
=================
Brief Summary
-----------------
Patients with intracerebral aneurysm will be screened for sleep apnea using out of center polysomnography/polygraphy. Baseline blood pressure and medication will be assessed. Patients will be followed for up to 5 years to examine the increase in aneurysm size, rupture rate and changes in medication.

Detailed Description
-----------------
Patient presenting to the outpatient center for neurological of neurosurgical management of intracerebral aneurysm will be recruited. Sleep apnea will be assessed by questionnaire and out of center polygraph/polysomnography. Medication, comorbidities and blood pressure will be recorded. Change in aneurysm size and blood pressure medication will be evaluated annually for up to 5 years. Frequency of subarachnoid hemorrhage and increase in aneurysm size will be assessed.

Official Title
-----------------
Incidence and Effects of Sleep Apnea on Intracerebral Aneurysms - IESA-Study

Conditions
-----------------
Sleep Apnea (Defined as Apnea Hypopnea Index > 5/h), Intracranial Aneurysm Size, Blood Pressure Medication, Comorbidities, Complications (Subarachnoid Hemorrhage)

Intervention / Treatment
-----------------
* Device: Cardiorepiratory Polygraphy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intracerebral aneurysm Age >= 18yrs. Ability to give informed consent Exclusion Criteria: Stroke within 3 month of study inclusion.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure medication | Blood pressure medication at baseline will be accessed. | Baseline | 
| Blood pressure | Blood pressure on baseline visit will be accessed. | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subarachnoid hemorrhage | Rate of aneurysm rupture and subarachnoid hemorrhage will be accessed annually. | 5 years | 
| Increase in size of aneurysm |  | 5 years | 
| Change in blood pressure medication | Blood pressure medication will be accessed on annual follow-up for up to 5 years. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep Apnea, Aneurysm, Subarachnoid Hemorrhage, Blood Pressure.